Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR-02: ctDNA-Guided Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer
NCT07562711Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of FOLFOX, Capecitabine + oxaliplatin and FOLFIRI in colorectal cancer (CRC) (2 arms), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 2 years. Started Nov 2024; status: recruiting.
02
Drugs
FOLFOXCapecitabine + oxaliplatinFOLFIRI
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07562711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07562711.